(Total Views: 532)
Posted On: 01/12/2022 10:53:07 AM
Post# of 151786
Over half of long-covid patients in this Italian study ended up with fatty liver disease.
Does it make sense that leronlimab's anti-NASH MOA would be relevant here?
https://www.medpagetoday.com/gastroenterology...ate_active
Does it make sense that leronlimab's anti-NASH MOA would be relevant here?
https://www.medpagetoday.com/gastroenterology...ate_active
(4)
(0)Scroll down for more posts ▼
